OBJECTIVES: We tested whether an assessment of myocardial scarring by cardiac magnetic resonance imaging (MRI) would improve risk stratification in patients evaluated for implantable cardioverter-defibrillator (ICD) implantation. BACKGROUND: Current sudden cardiac death risk stratification emphasizes left ventricular ejection fraction (LVEF); however, most patients suffering sudden cardiac death have a preserved LVEF, and many with poor LVEF do not benefit from ICD prophylaxis. METHODS: One hundred thirty-seven patients undergoing evaluation for possible ICD placement were prospectively enrolled and underwent cardiac MRI assessment of LVEF and scar. The pre-specified primary endpoint was death or appropriate ICD discharge for sustained ventricular tachyarrhythmia. RESULTS: During a median follow-up of 24 months the primary endpoint occurred in 39 patients. Whereas the rate of adverse events steadily increased with decreasing LVEF, a sharp step-up was observed for scar size >5% of left ventricular mass (hazard ratio [HR]: 5.2; 95% confidence interval [CI]: 2.0 to 13.3). On multivariable Cox proportional hazards analysis, including LVEF and electrophysiological-study results, scar size (as a continuous variable or dichotomized at 5%) was an independent predictor of adverse outcome. Among patients with LVEF >30%, those with significant scarring (>5%) had higher risk than those with minimal or no (≤5%) scarring (HR: 6.3; 95% CI: 1.4 to 28.0). Those with LVEF >30% and significant scarring had risk similar to patients with LVEF ≤30% (p = 0.56). Among patients with LVEF ≤30%, those with significant scarring again had higher risk than those with minimal or no scarring (HR: 3.9; 95% CI: 1.2 to 13.1). Those with LVEF ≤30% and minimal scarring had risk similar to patients with LVEF >30% (p = 0.71). CONCLUSIONS: Myocardial scarring detected by cardiac MRI is an independent predictor of adverse outcome in patients being considered for ICD placement. In patients with LVEF >30%, significant scarring (>5% LV) identifies a high-risk cohort similar in risk to those with LVEF ≤30%. Conversely, in patients with LVEF ≤30%, minimal or no scarring identifies a low-risk cohort similar to those with LVEF >30%.
OBJECTIVES: We tested whether an assessment of myocardial scarring by cardiac magnetic resonance imaging (MRI) would improve risk stratification in patients evaluated for implantable cardioverter-defibrillator (ICD) implantation. BACKGROUND: Current sudden cardiac death risk stratification emphasizes left ventricular ejection fraction (LVEF); however, most patients suffering sudden cardiac death have a preserved LVEF, and many with poor LVEF do not benefit from ICD prophylaxis. METHODS: One hundred thirty-seven patients undergoing evaluation for possible ICD placement were prospectively enrolled and underwent cardiac MRI assessment of LVEF and scar. The pre-specified primary endpoint was death or appropriate ICD discharge for sustained ventricular tachyarrhythmia. RESULTS: During a median follow-up of 24 months the primary endpoint occurred in 39 patients. Whereas the rate of adverse events steadily increased with decreasing LVEF, a sharp step-up was observed for scar size >5% of left ventricular mass (hazard ratio [HR]: 5.2; 95% confidence interval [CI]: 2.0 to 13.3). On multivariable Cox proportional hazards analysis, including LVEF and electrophysiological-study results, scar size (as a continuous variable or dichotomized at 5%) was an independent predictor of adverse outcome. Among patients with LVEF >30%, those with significant scarring (>5%) had higher risk than those with minimal or no (≤5%) scarring (HR: 6.3; 95% CI: 1.4 to 28.0). Those with LVEF >30% and significant scarring had risk similar to patients with LVEF ≤30% (p = 0.56). Among patients with LVEF ≤30%, those with significant scarring again had higher risk than those with minimal or no scarring (HR: 3.9; 95% CI: 1.2 to 13.1). Those with LVEF ≤30% and minimal scarring had risk similar to patients with LVEF >30% (p = 0.71). CONCLUSIONS: Myocardial scarring detected by cardiac MRI is an independent predictor of adverse outcome in patients being considered for ICD placement. In patients with LVEF >30%, significant scarring (>5% LV) identifies a high-risk cohort similar in risk to those with LVEF ≤30%. Conversely, in patients with LVEF ≤30%, minimal or no scarring identifies a low-risk cohort similar to those with LVEF >30%.
Authors: David Bello; Dipan J Shah; George M Farah; Silvia Di Luzio; Michele Parker; Maryl R Johnson; William G Cotts; Francis J Klocke; Robert O Bonow; Robert M Judd; Mihai Gheorghiade; Raymond J Kim Journal: Circulation Date: 2003-10-13 Impact factor: 29.690
Authors: Rainer Gradaus; Michael Block; Johannes Brachmann; Günter Breithardt; Hans G Huber; Werner Jung; Wolfgang Kranig; Ralph U Mletzko; Wolfgang Schoels; Karlheinz Seidl; Jochen Senges; Jürgen Siebels; Gerhard Steinbeck; Christoph Stellbrink; Dietrich Andresen Journal: Pacing Clin Electrophysiol Date: 2003-07 Impact factor: 1.976
Authors: Kyoko Soejima; William G Stevenson; John L Sapp; Andrew P Selwyn; Gregory Couper; Laurence M Epstein Journal: J Am Coll Cardiol Date: 2004-05-19 Impact factor: 24.094
Authors: Joseph B Selvanayagam; Steffen E Petersen; Jane M Francis; Matthew D Robson; Attila Kardos; Stefan Neubauer; David P Taggart Journal: Circulation Date: 2004-01-19 Impact factor: 29.690
Authors: E Wu; J T Ortiz; P Tejedor; D C Lee; C Bucciarelli-Ducci; P Kansal; J C Carr; T A Holly; D Lloyd-Jones; F J Klocke; R O Bonow Journal: Heart Date: 2007-12-10 Impact factor: 5.994
Authors: Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine Journal: N Engl J Med Date: 2004-05-20 Impact factor: 91.245
Authors: Heiko Mahrholdt; Anja Wagner; Michele Parker; Matthias Regenfus; David S Fieno; Robert O Bonow; Raymond J Kim; Robert M Judd Journal: J Am Coll Cardiol Date: 2003-08-06 Impact factor: 24.094
Authors: Muthiah Vaduganathan; Ravi B Patel; Robert J Mentz; Haris Subacius; Neal A Chatterjee; Stephen J Greene; Andrew P Ambrosy; Aldo P Maggioni; James E Udelson; Karl Swedberg; Marvin A Konstam; Christopher M O'Connor; Javed Butler; Mihai Gheorghiade; Faiez Zannad Journal: Am J Cardiol Date: 2018-04-11 Impact factor: 2.778
Authors: Ankur Gupta; Meagan Harrington; Christine M Albert; Navkaranbir S Bajaj; Jon Hainer; Victoria Morgan; Courtney F Bibbo; Paco E Bravo; Michael T Osborne; Sharmila Dorbala; Ron Blankstein; Viviany R Taqueti; Deepak L Bhatt; William G Stevenson; Marcelo F Di Carli Journal: JACC Clin Electrophysiol Date: 2018-07-25
Authors: Steven M Markowitz; Jonathan W Weinsaft; Louis Waldman; Maya Petashnick; Christopher F Liu; Jim W Cheung; George Thomas; James E Ip; Bruce B Lerman Journal: J Cardiovasc Electrophysiol Date: 2014-09-04
Authors: Jonathan D Kochav; Peter M Okin; Sean Wilson; Anika Afroz; Alfredo Renilla; Jonathan W Weinsaft Journal: Am J Cardiol Date: 2013-04-20 Impact factor: 2.778
Authors: Ivan Cokic; Avinash Kali; Hsin-Jung Yang; Raymond Yee; Richard Tang; Mourad Tighiouart; Xunzhang Wang; Warren S Jackman; Sumeet S Chugh; James A White; Rohan Dharmakumar Journal: Circ Cardiovasc Imaging Date: 2015-08 Impact factor: 7.792